For Novartis' Generic Advair, Another 18 Months Was Too Far Into The Unknown

 
• By Derrick Gingery

Company did not kill its development program because of US FDA feedback, but the experience seems to be another lesson in the difficulty in gaining approval for complex generics.

Neon Light Sign Lungs Icon
Novartis gave up in its attempt to become the second generic Advair to reach the US market. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics